## Mirko Manchia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9180513/publications.pdf

Version: 2024-02-01

153 papers 4,745 citations

33 h-index 61 g-index

164 all docs

164 docs citations

times ranked

164

6552 citing authors

#	Article	IF	Citations
1	Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic- a systematic review. European Neuropsychopharmacology, 2022, 54, 90-99.	0.7	5
2	Investigation of the Relationship among Cortisol, Pro-inflammatory Cytokines, and the Degradation of Tryptophan into Kynurenine in Patients with Major Depression and Suicidal Behavior. Current Topics in Medicinal Chemistry, 2022, 22, 2119-2125.	2.1	18
3	Overweight in mood disorders: Effects on morbidity and treatment response. Journal of Affective Disorders, 2022, 297, 169-175.	4.1	5
4	The impact of the prolonged COVID-19 pandemic on stress resilience and mental health: A critical review across waves. European Neuropsychopharmacology, 2022, 55, 22-83.	0.7	200
5	Sustained symptomatic remission in schizophrenia: Course and predictors from a two-year prospective study. Schizophrenia Research, 2022, 239, 34-41.	2.0	3
6	A review and meta-analysis of gene expression profiles in suicide. European Neuropsychopharmacology, 2022, 56, 39-49.	0.7	12
7	Using polygenic scores and clinical data for bipolar disorder patient stratification and lithium response prediction: machine learning approach. British Journal of Psychiatry, 2022, 220, 219-228.	2.8	11
8	Gut Microbiota Research in Bipolar Disorder and Possible Implications for Precision Psychiatry: A Systematic Review. Psychiatry International, 2022, 3, 114-121.	1.0	1
9	Suicide Risk and Lithium. JAMA Psychiatry, 2022, 79, 513.	11.0	5
10	Melatonin and aggressive behavior: A systematic review of the literature on preclinical and clinical evidence. Journal of Pineal Research, 2022, 72, .	7.4	7
11	Gut microbiota and treatment-resistant schizophrenia: many questions, fewer answers. Pharmacogenomics, 2022, 23, 277-280.	1.3	1
12	Is Poor Lithium Response in Individuals with Bipolar Disorder Associated with Increased Degradation of Tryptophan along the Kynurenine Pathway? Results of an Exploratory Study. Journal of Clinical Medicine, 2022, 11, 2517.	2.4	6
13	Physical exercise, depression, and anxiety in 2190 affective disorder subjects. Journal of Affective Disorders, 2022, 309, 172-177.	4.1	5
14	Indoleamine 2,3-dioxygenase (IDO)-activity in Severe Psychiatric Disorders: A Systemic Review. Current Topics in Medicinal Chemistry, 2022, 22, 2107-2118.	2.1	6
15	The Role of Magnesium in Pregnancy and in Fetal Programming of Adult Diseases. Biological Trace Element Research, 2021, 199, 3647-3657.	3.5	43
16	Association of polygenic score for major depression with response to lithium in patients with bipolar disorder. Molecular Psychiatry, 2021, 26, 2457-2470.	7.9	44
17	Big data in severe mental illness: the role of electronic monitoring tools and metabolomics. Personalized Medicine, 2021, 18, 75-90.	1.5	2
18	Exemplar scoring identifies genetically separable phenotypes of lithium responsive bipolar disorder. Translational Psychiatry, 2021, 11, 36.	4.8	16

#	Article	IF	CITATIONS
19	Prediction of lithium response using genomic data. Scientific Reports, 2021, 11, 1155.	3.3	11
20	Overview of CAPICEâ€"Childhood and Adolescence Psychopathology: unravelling the complex etiology by a large Interdisciplinary Collaboration in Europeâ€"an EU Marie SkÅ,odowska-Curie International Training Network. European Child and Adolescent Psychiatry, 2021, , 1.	4.7	2
21	Anatomical distribution and expression of <scp>CYP</scp> in humans: Neuropharmacological implications. Drug Development Research, 2021, 82, 628-667.	2.9	11
22	Copper-Induced Epigenetic Changes Shape the Clinical Phenotype in Wilson's Disease. Current Medicinal Chemistry, 2021, 28, 2707-2716.	2.4	2
23	DSM-5 and ICD-11 criteria for bipolar disorder: Implications for the prevalence of bipolar disorder and validity of the diagnosis – A narrative review from the ECNP bipolar disorders network. European Neuropsychopharmacology, 2021, 47, 54-61.	0.7	25
24	Predominant Polarity and Polarity Index of Maintenance Treatments for Bipolar Disorder: A Validation Study in a Large Naturalistic Sample in Italy. Medicina (Lithuania), 2021, 57, 598.	2.0	2
25	Protocol for a pharmacogenetic study of antidepressants. Psychiatric Genetics, 2021, Publish Ahead of Print, 186-193.	1.1	1
26	Involvement of Gut Microbiota in Schizophrenia and Treatment Resistance to Antipsychotics. Biomedicines, 2021, 9, 875.	3.2	21
27	Characterisation of age and polarity at onset in bipolar disorder. British Journal of Psychiatry, 2021, 219, 659-669.	2.8	20
28	Increased Câ€reactive protein concentration and suicidal behavior in people with psychiatric disorders: A systematic review and metaâ€analysis. Acta Psychiatrica Scandinavica, 2021, 144, 537-552.	4.5	31
29	Leukocytosis Associated with Clozapine Treatment: A Case Series and Systematic Review of the Literature. Medicina (Lithuania), 2021, 57, 816.	2.0	9
30	Suicidal risks in rural versus urban populations in Sardinia. Journal of Affective Disorders, 2021, 295, 1449-1455.	4.1	2
31	Variations in seasonal solar insolation are associated with a history of suicide attempts in bipolar I disorder. International Journal of Bipolar Disorders, 2021, 9, 26.	2.2	6
32	HLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders. Scientific Reports, 2021, 11, 17823.	3.3	10
33	Duration of untreated illness and bipolar disorder: time for a new definition? Results from a cross-sectional study. Journal of Affective Disorders, 2021, 294, 513-520.	4.1	9
34	Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients. Translational Psychiatry, 2021, 11, 606.	4.8	25
35	Prediction of lithium response using clinical data. Acta Psychiatrica Scandinavica, 2020, 141, 131-141.	4.5	50
36	An examination of the quality and performance of the Alda scale for classifying lithium response phenotypes. Bipolar Disorders, 2020, 22, 255-265.	1.9	24

#	Article	IF	CITATIONS
37	P.266 Analysis of gut microbiota composition in patients with major depressive disorder characterized as treatment resistant or responders to antidepressants. European Neuropsychopharmacology, 2020, 40, S152.	0.7	0
38	P.353 Peripheral melatonin levels in bipolar disorder: preliminary results of a cross-sectional analysis. European Neuropsychopharmacology, 2020, 40, S205-S206.	0.7	0
39	Editorial: Decreasing the Impact of Treatment Resistance in Schizophrenia: Identifying Novel Molecular Targets/Pathways to Increase Treatment Efficacy. Frontiers in Pharmacology, 2020, 11, 1001.	3.5	0
40	Telomere attrition and inflammatory load in severe psychiatric disorders and in response to psychotropic medications. Neuropsychopharmacology, 2020, 45, 2229-2238.	5.4	21
41	Comparison of Conventional Statistical Methods with Machine Learning in Medicine: Diagnosis, Drug Development, and Treatment. Medicina (Lithuania), 2020, 56, 455.	2.0	178
42	Exploring the Role of Gut Microbiota in Major Depressive Disorder and in Treatment Resistance to Antidepressants. Biomedicines, 2020, 8, 311.	3.2	34
43	<p>Challenges and Future Prospects of Precision Medicine in Psychiatry</p> . Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 127-140.	0.7	42
44	Differences in telomere length between patients with bipolar disorder and controls are influenced by lithium treatment. Pharmacogenomics, 2020, 21, 533-540.	1.3	26
45	Stress resilience during the coronavirus pandemic. European Neuropsychopharmacology, 2020, 35, 12-16.	0.7	285
46	Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia. Frontiers in Psychiatry, 2020, 11, 369.	2.6	25
47	The Impact of Alexithymia on Treatment Response in Psychiatric Disorders: A Systematic Review. Frontiers in Psychiatry, 2020, 11, 311.	2.6	31
48	Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action. European Neuropsychopharmacology, 2020, 36, 121-136.	0.7	17
49	Clinical, genetic, and brain imaging predictors of risk for bipolar disorder in high-risk individuals. Expert Review of Molecular Diagnostics, 2020, 20, 327-333.	3.1	7
50	Can network analysis shed light on predictors of lithium response in bipolar I disorder?. Acta Psychiatrica Scandinavica, 2020, 141, 522-533.	4.5	13
51	A multidisciplinary approach to mental illness: do inflammation, telomere length and microbiota form a loop? A protocol for a cross-sectional study on the complex relationship between inflammation, telomere length, gut microbiota and psychiatric disorders. BMJ Open, 2020, 10, e032513.	1.9	10
52	Clinical response and metabolic effects of lithium in 323 mood disorder patients. Journal of Affective Disorders, 2020, 270, 9-14.	4.1	3
53	The Role of Gut Microbiota in the High-Risk Construct of Severe Mental Disorders: A Mini Review. Frontiers in Psychiatry, 2020, 11, 585769.	2.6	13
54	Neurobiology of Violence. Comprehensive Approach To Psychiatry, 2020, , 25-47.	1.0	4

#	Article	IF	CITATIONS
55	The biology of aggressive behavior in bipolar disorder: A systematic review. Neuroscience and Biobehavioral Reviews, 2020, 119, 9-20.	6.1	13
56	Lithium's antiviral effects: a potential drug for CoViD-19 disease?. International Journal of Bipolar Disorders, 2020, 8, 21.	2.2	52
57	Prevalence and clinical correlates of cognitive symptoms in depression: a naturalistic study. Rivista Di Psichiatria, 2020, 55, 301-307.	0.6	2
58	Investigating polygenic burden in age at disease onset in bipolar disorder: Findings from an international multicentric study. Bipolar Disorders, 2019, 21, 68-75.	1.9	20
59	Clinical and genetic determinants of serum brain-derived neurotrophic factor (BDNF) levels in psychotic patients: A longitudinal prospective study. European Neuropsychopharmacology, 2019, 29, S133-S134.	0.7	0
60	Clinical use of lithium salts: guide for users and prescribers. International Journal of Bipolar Disorders, 2019, 7, 16.	2.2	126
61	Overview of Federated Facility to Harmonize, Analyze and Management of Missing Data in Cohorts. Applied Sciences (Switzerland), 2019, 9, 4103.	2.5	5
62	Biomarkers in aggression. Advances in Clinical Chemistry, 2019, 93, 169-237.	3.7	17
63	Translating preclinical findings in clinically relevant new antipsychotic targets: focus on the glutamatergic postsynaptic density. Implications for treatment resistant schizophrenia. Neuroscience and Biobehavioral Reviews, 2019, 107, 795-827.	6.1	17
64	F141IDENTIFICATION OF PERIPHERAL BIOMARKERS IN SCHIZOPHRENIA: A META-ANALYSIS OF MICROARRAY GENE-EXPRESSION DATASETS. European Neuropsychopharmacology, 2019, 29, S1186-S1187.	0.7	0
65	Lithium pharmacogenetics. Psychiatry Research, 2019, 279, 401.	3.3	1
66	Lithium and bipolar depression. Bipolar Disorders, 2019, 21, 458-459.	1.9	4
67	Association between solar insolation and a history of suicide attempts in bipolar I disorder. Journal of Psychiatric Research, 2019, 113, 1-9.	3.1	25
68	P.049 The impact of depot and long acting injectable antipsychotics on BDNF serum levels in psychosis: a 24-month longitudinal prospective study. European Neuropsychopharmacology, 2019, 29, S54-S55.	0.7	0
69	Attention deficit-hyperactivity disorder in adult bipolar disorder patients. Journal of Affective Disorders, 2019, 243, 391-396.	4.1	35
70	Peripheral Biomarkers in Schizophrenia: A Meta-Analysis of Microarray Gene Expression Datasets. International Journal of Neuropsychopharmacology, 2019, 22, 186-193.	2.1	19
71	Role of palmitoylethanolamide (PEA) in depression: Translational evidence. Journal of Affective Disorders, 2019, 255, 195-200.	4.1	22
72	Investigating the relationship between melatonin levels, melatonin system, microbiota composition and bipolar disorder psychopathology across the different phases of the disease. International Journal of Bipolar Disorders, 2019, 7, 27.	2.2	11

#	Article	IF	Citations
73	Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder. JAMA Psychiatry, 2018, 75, 65-74.	11.0	102
74	Association study of BDNF and DRD3 genes with alcohol use disorder in Schizophrenia. Neuroscience Letters, 2018, 671, 1-6.	2.1	11
75	Clinical and biological predictors of response to electroconvulsive therapy (ECT): a review. Neuroscience Letters, 2018, 669, 32-42.	2.1	79
76	Personalized psychiatry: Promises and pitfalls. Neuroscience Letters, 2018, 669, 1-2.	2.1	5
77	Personalized management of bipolar disorder. Neuroscience Letters, 2018, 669, 3-9.	2.1	28
78	A parsimonious approach to suicide prevention in mood disorders. Bipolar Disorders, 2018, 20, 570-570.	1.9	0
79	Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder. Frontiers in Psychiatry, 2018, 9, 207.	2.6	28
80	Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study. BMJ Open, 2017, 7, e014938.	1.9	5
81	Clinicians' adherence to clinical practice guidelines for cardiac function monitoring during antipsychotic treatment: a retrospective report on 434 patients with severe mental illness. BMC Psychiatry, 2017, 17, 121.	2.6	6
82	Targeting aggression in severe mental illness: The predictive role of genetic, epigenetic, and metabolomic markers. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 77, 32-41.	4.8	30
83	Serotonin Dysfunction, Aggressive Behavior, and Mental Illness: Exploring the Link Using a Dimensional Approach. ACS Chemical Neuroscience, 2017, 8, 961-972.	3.5	59
84	Solar insolation in springtime influences age of onset of bipolar I disorder. Acta Psychiatrica Scandinavica, 2017, 136, 571-582.	4.5	24
85	Pattern of gene expression in different stages of schizophrenia: Down-regulation of NPTX2 gene revealed by a meta-analysis of microarray datasets. European Neuropsychopharmacology, 2017, 27, 1054-1063.	0.7	28
86	Evaluation of research topic evolution in psychiatry using co-word analysis. Medicine (United States), 2017, 96, e7349.	1.0	21
87	The longitudinal trajectory of serum brain-derived neurotrophic factor (BDNF) levels in psychotic patients: a prospective observational study. European Neuropsychopharmacology, 2017, 27, S913.	0.7	2
88	Preventing aggressive/violent behavior: a role for biomarkers?. Biomarkers in Medicine, 2017, 11, 701-704.	1.4	0
89	Cutaneous adverse reaction during lithium treatment: a case report and updated systematic review with meta-analysis. International Journal of Bipolar Disorders, 2017, 5, 20.	2.2	8
90	Long-term lithium treatment in bipolar disorder: effects on glomerular filtration rate and other metabolic parameters. International Journal of Bipolar Disorders, 2017, 5, 27.	2.2	81

#	Article	IF	Citations
91	Clinical correlates of age at onset distribution in bipolar disorder: a comparison between diagnostic subgroups. International Journal of Bipolar Disorders, 2017, 5, 28.	2.2	14
92	Assessment of eating disorders with the diabetes eating problems survey – revised (DEPS-R) in a representative sample of insulin-treated diabetic patients: a validation study in Italy. BMC Psychiatry, 2017, 17, 262.	2.6	43
93	Immunohistochemical markers of CYP3A4 and CYP3A7: a new tool towards personalized pharmacotherapy of hepatocellular carcinoma. European Journal of Histochemistry, 2016, 60, 2614.	1.5	15
94	BDNF serum levels as a biomarker of depressive symptoms in psychotic disorders. European Neuropsychopharmacology, 2016, 26, S365-S366.	0.7	0
95	Clinical correlates of age at onset distribution in bipolar disorder: a comparison between diagnostic subgroups. European Neuropsychopharmacology, 2016, 26, S431.	0.7	0
96	Clinicians' attitudes to cardiac function monitoring guidelines during antipsychotic treatment: a retrospective report on 434 patients with severe mental illness. European Neuropsychopharmacology, 2016, 26, S536-S537.	0.7	0
97	Eating disorders: What age at onset?. Psychiatry Research, 2016, 238, 225-227.	3.3	150
98	Fetal programming of neuropsychiatric disorders. Birth Defects Research Part C: Embryo Today Reviews, 2016, 108, 207-223.	3.6	117
99	Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. Human Molecular Genetics, 2016, 25, 3383-3394.	2.9	182
100	Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet, The, 2016, 387, 1085-1093.	13.7	306
101	Diagnostic reliability in schizoaffective disorder. Bipolar Disorders, 2016, 18, 78-80.	1.9	12
102	What happens to the course of bipolar disorder after electroconvulsive therapy?. Journal of Affective Disorders, 2016, 195, 180-184.	4.1	9
103	Haloperidol and loss of gray matter in schizophrenia: Reconciling meta-analytical results with molecular pharmacology. Psychiatry Research, 2016, 235, 209-210.	3.3	0
104	Effect of Interacting Nonsteroidal Anti-Inflammatory Agents (NSAIDs) and Opioids on Mood. , 2016, , 111-119.		0
105	Admixture analysis of age at symptom onset and age at disorder onset in a large sample of patients with obsessive–compulsive disorder. Journal of Affective Disorders, 2015, 187, 188-196.	4.1	23
106	Influence of birth cohort on age of onset cluster analysis in bipolar I disorder. European Psychiatry, 2015, 30, 99-105.	0.2	28
107	Influence of light exposure during early life on the age of onset of bipolar disorder. Journal of Psychiatric Research, 2015, 64, 1-8.	3.1	39
108	Efficacy and safety of electroconvulsive therapy in the first trimester of pregnancy: a case of severe manic catatonia. Bipolar Disorders, 2015, 17, 567-571.	1.9	10

#	Article	IF	Citations
109	Investigation of the genetic interaction between <i>BDNF</i> and <i>DRD3</i> genes in suicidal behaviour in psychiatric disorders. World Journal of Biological Psychiatry, 2015, 16, 171-179.	2.6	14
110	An Introduction to Pharmacogenomics and Personalized Medicine., 2015,, 1053-1065.		1
111	The role of anti-glutamic acid decarboxylase autoantibodies in mood disorders. Neuroimmunology and Neuroinflammation, 2015, 2, 237.	1.4	2
112	Variant $\langle i \rangle$ GADL1 $\langle i \rangle$ and Response to Lithium in Bipolar I Disorder. New England Journal of Medicine, 2014, 370, 1855-1860.	27.0	36
113	Prognostic models in bipolar disorder: can the prediction of the long-term clinical course rely on the integration of clinical and molecular data?. Biomarkers in Medicine, 2014, 8, 371-374.	1.4	2
114	Lithium-induced differential expression of SAT1 in suicide completers and controls is not correlated with polymorphisms in the promoter region of the gene. Psychiatry Research, 2014, 220, 1167-1168.	3.3	1
115	Association Study of <b><i>GABRG2</i></b> Polymorphisms with Suicidal Behaviour in Schizophrenia Patients with Alcohol Use Disorder. Neuropsychobiology, 2014, 69, 154-158.	1.9	12
116	Relationship between sunlight and the age of onset of bipolar disorder: An international multisite study. Journal of Affective Disorders, 2014, 167, 104-111.	4.1	43
117	Continuation Versus Discontinuation of Lithium During Pregnancy. Journal of Clinical Psychopharmacology, 2014, 34, 407-410.	1.4	10
118	Pharmacogenomics and Personalized Medicine: Bridging Genetic Knowledge and Clinical Practice. , 2014, , 1-16.		0
119	Insulin-like growth factor 1 (IGF-1) expression is up-regulated in lymphoblastoid cell lines of lithium responsive bipolar disorder patients. Pharmacological Research, 2013, 73, 1-7.	7.1	66
120	No association of endocannabinoid genes with bipolar disorder or lithium response in a Sardinian sample. Psychiatry Research, 2013, 210, 887-890.	3.3	12
121	Pharmacogenomics of bipolar disorder. Pharmacogenomics, 2013, 14, 655-674.	1.3	28
122	Differential effect of lithium on spermidine/spermine N1-acetyltransferase expression in suicidal behaviour. International Journal of Neuropsychopharmacology, 2013, 16, 2209-2218.	2.1	21
123	Repeated Erythromycin/Codeine-Induced Psychotic Mania. Clinical Neuropharmacology, 2013, 36, 177-178.	0.7	9
124	Genetic risk of suicidal behavior in bipolar spectrum disorder: analysis of 737 pedigrees. Bipolar Disorders, 2013, 15, 496-506.	1.9	36
125	The Impact of Phenotypic and Genetic Heterogeneity on Results of Genome Wide Association Studies of Complex Diseases. PLoS ONE, 2013, 8, e76295.	2.5	177
126	Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. PLoS ONE, 2013, 8, e65636.	2.5	156

#	Article	IF	CITATIONS
127	The brain-derived neurotrophic factor gene in suicidal behaviour: a meta-analysis. International Journal of Neuropsychopharmacology, 2012, 15, 1037-1042.	2.1	71
128	Evaluation of Lithium Response in Episodic Cluster Headache: A Retrospective Case Series. Headache, 2012, 52, 1171-1175.	3.9	16
129	Impact of sunlight on the age of onset of bipolar disorder. Bipolar Disorders, 2012, 14, 654-663.	1.9	39
130	Evidence for association of an <i>ACCN1</i> gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics, 2011, 12, 1559-1569.	1.3	82
131	Are serotonin 3A and 3B receptor genes associated with suicidal behavior in schizophrenia subjects?. Neuroscience Letters, 2011, 489, 137-141.	2.1	6
132	Admixture analysis of age at onset in bipolar disorder. Psychiatry Research, 2011, 185, 27-32.	3.3	51
133	Age at onset in bipolar disorder: Investigation of the role of TaqIA polymorphism of <i>DRD2</i> gene in a Sardinian sample. European Psychiatry, 2011, 26, 141-143.	0.2	13
134	A Retrospective Case Series of Bipolar Patients With Adjunctive Carbamazepine in Long-Term Lithium Treatment. Journal of Clinical Psychopharmacology, 2011, 31, 538-540.	1.4	1
135	Outcome measures in a bipolar disorder. International Clinical Psychopharmacology, 2011, 26, e19.	1.7	0
136	Mixture Analysis of Age at Onset in Migraine Without Aura: Evidence for Three Subgroups. Headache, 2010, 50, 1313-1319.	3.9	9
137	The International Consortium on Lithium Genetics (ConLiGen): An Initiative by the NIMH and IGSLI to Study the Genetic Basis of Response to Lithium Treatment. Neuropsychobiology, 2010, 62, 72-78.	1.9	134
138	Pharmacogenomics of Mood Stabilizers in the Treatment of Bipolar Disorder. Human Genomics and Proteomics, 2010, 2, 159761.	1.5	19
139	Smoking in adult attention-deficit/hyperactivity disorder: Interaction between 15q13 nicotinic genes and Temperament Character Inventory scores. World Journal of Biological Psychiatry, 2010, 11, 506-510.	2.6	3
140	Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics, 2010, 11, 1149-1167.	1.3	129
141	Age at onset in Canadian Schizophrenia patients: Admixture analysis. Schizophrenia Research, 2010, 122, 278-279.	2.0	21
142	Association study of BDNF and DRD3 genes in schizophrenia diagnosis using matched case–control and family based study designs. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1412-1418.	4.8	18
143	Mixture regression analysis on age at onset in Bipolar Disorder patients: Investigation of the role of serotonergic genes. European Neuropsychopharmacology, 2010, 20, 663-670.	0.7	15
144	Smoking in adult attention-deficit/hyperactivity disorder: Interaction between 15q13 nicotinic genes and Temperament Character Inventory scores. World Journal of Biological Psychiatry, 2010, 11, 1-5.	2.6	2

#	Article	IF	Citations
145	Migraine and tumour necrosis factor gene polymorphism. Journal of Neurology, 2009, 256, 194-197.	3.6	27
146	The diacylglycerol kinase eta gene and bipolar disorder: a replication study in a Sardinian sample. Molecular Psychiatry, 2009, 14, 350-351.	7.9	36
147	Association study in a Sardinian sample between bipolar disorder and the nuclear receptor ⟨i⟩REVâ€ERBα⟨li⟩ gene, a critical component of the circadian clock system. Bipolar Disorders, 2009, 11, 215-220.	1.9	66
148	No association between lithium full responders and the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes in a Sardinian sample. Psychiatry Research, 2009, 169, 164-166.	3.3	25
149	Interacting genes in lithium prophylaxis: Preliminary results of an exploratory analysis on the role of DGKH and NR1D1 gene polymorphisms in 199 Sardinian bipolar patients. Neuroscience Letters, 2009, 467, 67-71.	2.1	41
150	Age at onset in Sardinian bipolar I patients: evidence for three subgroups. Bipolar Disorders, 2008, 10, 443-446.	1.9	58
151	The PDLIM5 gene and lithium prophylaxis: An association and gene expression analysis in Sardinian patients with bipolar disorder. Pharmacological Research, 2008, 57, 369-373.	7.1	27
152	A case–control association study of the PDLIM5 gene and bipolar disorder in a Sardinian sample. Psychiatric Genetics, 2008, 18, 128-132.	1.1	6
153	Depression in Diabetic Patients: What Is the Link With Eating Disorders? Results of a Study in a Representative Sample of Patients With Type $1$ Diabetes. Frontiers in Psychiatry, 0, $13$ , .	2.6	6